A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane) as Chemoimmunotherapy for Platinum- Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer.

Trial Profile

A Phase II Trial of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) With Weekly Protein Bound Paclitaxel (Abraxane) as Chemoimmunotherapy for Platinum- Refractory/Resistant Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 30 Aug 2017

At a glance

  • Drugs Sargramostim (Primary) ; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jun 2015 Results assessing immune responses presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 10 Apr 2012 Additional trial identifier identified as reported by ClinicalTrials.gov.
    • 29 Mar 2012 Actual patient number (21) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top